Venlafaxine News and Research RSS Feed - Venlafaxine News and Research

Venlafaxine is an antidepressant drug that is being evaluated for the treatment of hot flashes in women who have breast cancer.
Estrogen therapy and venlafaxine treatment effective for hot flashes, night sweats

Estrogen therapy and venlafaxine treatment effective for hot flashes, night sweats

A new research study from Brigham and Women's Hospital (BWH) that compares low-dose oral estrogen and low-dose non-hormonal venlafaxine hydrochloride extended release (XR) to placebo were both found effective in reducing the number of hot flashes and night sweats reported by menopausal women. [More]
IQWiG completes first health economic evaluation

IQWiG completes first health economic evaluation

The German Institute for Quality and Efficiency in Health Care has completed its first health economic evaluation. The report on antidepressants published on 30 October 2013 shows that the "efficiency frontier method" works and can provide very helpful results. [More]
Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Janssen-Cilag International NV (Janssen) announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of the oral, once-daily medication ZYTIGA for use in combination with prednisone or prednisolone in the treatment of metastatic castration-resistant prostate cancer (mCRPC), in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated. [More]
Newer antidepressant decreases depression in Parkinson's patients without worsening motor problems

Newer antidepressant decreases depression in Parkinson's patients without worsening motor problems

Certain antidepressants appear to decrease depression in people with Parkinson's disease without worsening motor problems, according to a study published in the April 11, 2012, online issue of Neurology, the medical journal of the American Academy of Neurology. [More]
Switching or adding antidepressants does not exacerbate side effects

Switching or adding antidepressants does not exacerbate side effects

Patients with major depression who fail to see improvement after taking an antidepressant often have their initial medication switched or combined with a second drug. Many clinicians weigh the possibility of adverse side effects when deciding between strategies. New research in the latest issue of General Hospital Psychiatry now suggests one strategy may not be any more likely to be harmful than the other. [More]
New generation antidepressants may increase risk of adverse outcomes in elderly

New generation antidepressants may increase risk of adverse outcomes in elderly

Older people taking new generation antidepressants are at more risk of dying or suffering from a range of serious health conditions including stroke, falls, fractures and epilepsy, a study involving researchers at The University of Nottingham has found. [More]
New antidepressant prescription linked to increased risk of falls in nursing home residents

New antidepressant prescription linked to increased risk of falls in nursing home residents

Nursing home residents taking certain antidepressant medications are at an increased risk of falling in the days following the start of a new prescription or a dose increase of their current drug, according to a new study by the Institute for Aging Research of Hebrew SeniorLife, an affiliate of Harvard Medical School. [More]
Dr. Reddy’s launches generic ARICEPT, EFFEXOR XR and FEMARA in the US

Dr. Reddy’s launches generic ARICEPT, EFFEXOR XR and FEMARA in the US

Dr. Reddy's Laboratories today announced that it has launched three products in the US market. [More]
FDA approves Mylan's ANDA for Venlafaxine HCl ER Capsules to treat depressive, anxiety disorder

FDA approves Mylan's ANDA for Venlafaxine HCl ER Capsules to treat depressive, anxiety disorder

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Venlafaxine Hydrochloride Extended-release Capsules, 37.5 mg (base), 75 mg (base) and 150 mg (base), the generic version of Wyeth's Effexor XR Capsules, which are used in the treatment of major depressive disorder and social anxiety disorder. [More]
Otsuka Pharmaceutical reports OPC-34712 Phase 2 trial results in major depressive disorder

Otsuka Pharmaceutical reports OPC-34712 Phase 2 trial results in major depressive disorder

Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) today announced results from a Phase 2 clinical trial of OPC-34712, a novel D2 dopamine partial agonist investigational product. [More]
Study: Dual medications do not hasten recovery from depression

Study: Dual medications do not hasten recovery from depression

Taking two medications for depression does not hasten recovery from the condition that affects 19 million Americans each year, researchers at UT Southwestern Medical Center have found in a national study. [More]
New guideline on most effective treatments for diabetic nerve pain

New guideline on most effective treatments for diabetic nerve pain

The American Academy of Neurology has issued a new guideline on the most effective treatments for diabetic nerve pain, the burning or tingling pain in the hands and feet that affects millions of people with diabetes. The guideline is published in the April 11, 2011, online issue of Neurology®, the medical journal of the American Academy of Neurology, and will be presented April 11, 2011, at the American Academy of Neurology's Annual Meeting in Honolulu. [More]

Prolonged exposure to antidepressants can induce tardive dysphoria

In the current issue of Psychotherapy and Psychosomatics a new important side effect of antidepressant drugs is described: tardive dysphoria. [More]
Teva fourth quarter net sales increase 16% to record $4.4 billion

Teva fourth quarter net sales increase 16% to record $4.4 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter and year ended December 31, 2010. [More]
Breast cancer patients taking tamoxifen anxious to have CYP2D6 genetic test

Breast cancer patients taking tamoxifen anxious to have CYP2D6 genetic test

While the medical community continues to debate the benefits of CYP2D6 genetic testing for women on the breast cancer treatment tamoxifen, patients using the medication are anxious to have the tests. According to a new survey of more than 700 women with breast cancer currently taking tamoxifen, almost 80 percent of respondents would choose to have a genetic test that determines CYP2D6 genotype, yet only 14 percent of these women have been tested. CYP2D6 is an enzyme that influences how well the body processes tamoxifen into its more active form. [More]
Teva third quarter net sales increase 20% to $4.3 billion

Teva third quarter net sales increase 20% to $4.3 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended September 30, 2010. [More]
Study finds acupuncture can control side effects of cancer treatment

Study finds acupuncture can control side effects of cancer treatment

Recent studies have shown that acupuncture can help control a number of symptoms and side effects such as pain, fatigue, dry mouth, nausea, and vomiting associated with a variety of cancers and their treatments. [More]
USFDA approves Sun Pharma's generic Venlafaxine Hydrochloride Extended Release tablets ANDA

USFDA approves Sun Pharma's generic Venlafaxine Hydrochloride Extended Release tablets ANDA

Sun Pharma announced that USFDA has granted an approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Venlafaxine Hydrochloride Extended Release tablets. [More]
Intellipharmaceutics provides update on generic version of Effexor XR

Intellipharmaceutics provides update on generic version of Effexor XR

Intellipharmaceutics International Inc., today announced the following with regard to its generic drug commercialization activities. [More]
Teva launches antidepressant Venlafaxine HCl ER Capsules

Teva launches antidepressant Venlafaxine HCl ER Capsules

Teva Pharmaceutical Industries Ltd. announced today that it has commenced commercial launch of Venlafaxine HCl ER Capsules, the Company's generic version of Wyeth's antidepressant Effexor XR®. The brand product had annual sales of approximately $2.75 billion in the United States, based on IMS sales data. [More]